For example, a body mass loss of 3–5% could decrease cardiovascular risk, a body mass loss of 2–5% lower the level of HbA1c in T2DM patients, and a body mass loss of 7–10% could improve insulin sensitivity, liver enzyme concentrations, and liver steatosis and fibrosis in obese NAFLD patients (10, 31). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.